Effect of supplementation in treatment of women with gestational diabetes

Clinical trial of the effect of multi mineral-vitamin D supplementation compared with the placebo on metabolic profiles in women with gestational diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201706045623N116

Enrollment

Registered

2017-06-18

Start date

2017-05-05

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes. Diabetes mellitus in pregnancy, unspecified

Interventions

Intervention 1: Intervention group: Multi mineral-vitamin D supplements (Vitane, Wolfratshausen, Germany), 800 mg calcium, 200 mg magnesium, 8 mg zinc, 400 IU vitamin D3, daily, for 6 weeks orally. In

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with gestational diabetes Aged 18 to 40 years

Exclusion criteria

Exclusion criteria: Intake of magnesium, zinc, calcium and/or vitamin D supplements during the last 3 months Taking insulin Placenta abruption Pre-eclampsia Eclampsia Hypo and hyperthyroidism Smokers

Design outcomes

Primary

Measure	Time frame
Insulin. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Using HOMA formula.	—

Secondary

Measure	Time frame
Triglycerides. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;LDL. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;VLDL. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;FPG. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.	—

Measure

Time frame

Triglycerides. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;LDL. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;VLDL. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;FPG. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026